Press release
Deadline on Jan. 8th coming up in Lawsuit for certain investors in SCYNEXIS, Inc. (NASDAQ: SCYX)
A Deadline is coming up on January 08, 2024 in the lawsuit for certain investors in SCYNEXIS, Inc. (NASDAQ: SCYX).
Investors who purchased shares of SCYNEXIS, Inc. (NASDAQ: SCYX) have certain options and there are strict and short deadlines running. Deadline: January 08, 2024. SCYNEXIS, Inc. (NASDAQ: SCYX) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges on behalf of purchasers of SCYNEXIS, Inc. (NASDAQ: SCYX) common shares between March 31, 2023 and September 22, 2023, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 31, 2023 and September 22, 2023 the Defendants failed to disclose to investors that the equipment used to manufacture ibrexafungerp was also used to manufacture a non-antibacterial beta-lactam drug substance, presenting a risk of cross-contamination, that the Company did not have effective internal controls and procedures, as well as adequate internal oversight policies to ensure that its vendor complied with current Good Manufacturing Practices (cGMP), that, due to the substantial risk of cross-contamination, Scynexis was reasonably likely to recall its ibrexafungerp tablets and halt its clinical studies, and that as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Those who purchased shares of SCYNEXIS, Inc. (NASDAQ: SCYX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on Jan. 8th coming up in Lawsuit for certain investors in SCYNEXIS, Inc. (NASDAQ: SCYX) here
News-ID: 3346007 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for SCYNEXIS
Blastomycosis Treatment Market Overall Study Report 2025-2032 | Janssen, Scynexi …
The blastomycosis treatment market is estimated to be valued at USD 216.3 Mn in 2025 and is expected to reach USD 349.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 7.1% from 2025 to 2032.
The release of the report "Blastomycosis Treatment Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2032". This includes examining past deployments, current market conditions, and expected future deployments. This…
Systemic Inflammatory Response Syndrome Market to Rise by 2032 | Cidera Therapeu …
DelveInsight's "Systemic Inflammatory Response Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Systemic Inflammatory Response Syndrome, historical and forecasted epidemiology as well as the Systemic Inflammatory Response Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Systemic Inflammatory Response Syndrome market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and…
Investigation announced for Long-Term Investors in shares of SCYNEXIS, Inc. (NAS …
An investigation was announced for long-term investors in shares of SCYNEXIS, Inc. (NASDAQ: SCYX) concerning potential breaches of fiduciary duties by certain directors of SCYNEXIS, Inc.
Investors who are current long term investors in SCYNEXIS, Inc. (NASDAQ: SCYX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: SCYX stocks…
Lawsuit filed for Investors who lost money with shares of SCYNEXIS, Inc. (NASDAQ …
An investor, who purchased shares of SCYNEXIS, Inc. (NASDAQ: SCYX), filed a lawsuit over alleged violations of Federal Securities Laws by SCYNEXIS, Inc.
Investors who purchased shares of SCYNEXIS, Inc. (NASDAQ: SCYX) have certain options and for certain investors are short and strict deadlines running. Deadline: January 08, 2024. NASDAQ: SCYX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Jersey City, NJ based SCYNEXIS, Inc., a…
Systemic Inflammatory Response Syndrome Market to Witness Growth by 2032 | Compa …
DelveInsight's "Systemic Inflammatory Response Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Systemic Inflammatory Response Syndrome, historical and forecasted epidemiology as well as the Systemic Inflammatory Response Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Systemic Inflammatory Response Syndrome market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and…
Evotec & Scynexis to lead the workshops for Superbugs & Superdrugs 2020
SMi Reports: Interactive workshop overview for SMi's 22nd Annual Superbugs & Superdrugs Conference, London in March 2020
SMi’s highly anticipated 22nd Annual Superbugs & Superdrugs Conference will commence on the 30th and 31st March 2020 and in London, UK.
For this year’s conference, industry leaders and key profiles from leading pharmaceutical organisations will be brought together to discuss the strategies in place that reduce AMR, evaluate the role pharmaceutical companies and funding…
